{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:43:49Z","timestamp":1762083829612,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Amgen Pharmaceuticals","award":["20167888"],"award-info":[{"award-number":["20167888"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Novel biomarkers for tumour burden and bone disease are required to guide clinical management of plasma cell dyscrasias. Recently, bone turnover markers (BTMs) and Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) have been explored, although their role in the prospective assessment of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) is unclear. Here, we conducted a pilot observational cohort feasibility study combining serum BTMs and DW-MRI in addition to standard clinical assessment. Fifty-five patients were recruited (14 MGUS, 15 smouldering MM, 14 new MM and 12 relapsed MM) and had DW-MRI and serum biomarkers (P1NP, CTX-1, ALP, DKK1, sclerostin, RANKL:OPG and BCMA) measured at baseline and 6-month follow-up. Serum sclerostin positively correlated with bone mineral density (r = 0.40\u22120.54). At baseline, serum BCMA correlated with serum paraprotein (r = 0.42) and serum DKK1 correlated with serum free light chains (r = 0.67); the longitudinal change in both biomarkers differed between International Myeloma Working Group (IMWG)-defined responders and non-responders. Myeloma Response Assessment and Diagnosis System (MY-RADS) scoring of serial DW-MRI correlated with conventional IMWG response criteria for measuring longitudinal changes in tumour burden. Overall, our pilot study suggests candidate radiological and serum biomarkers of tumour burden and bone loss in MM\/MGUS, which warrant further exploration in larger cohorts to validate the findings and to better understand their clinical utility.<\/jats:p>","DOI":"10.3390\/cancers15010095","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T07:31:56Z","timestamp":1672126316000},"page":"95","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers"],"prefix":"10.3390","volume":"15","author":[{"given":"Gaurav","family":"Agarwal","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Nador","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherin","family":"Varghese","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK"},{"name":"Oxford Translational Myeloma Centre, Oxford OX3 7LD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiwot","family":"Getu","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Palmer","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Watson","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Pereira","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germana","family":"Sallemi","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Partington","sequence":"additional","affiliation":[{"name":"Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neel","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-2672","authenticated-orcid":false,"given":"Rajkumar","family":"Soundarajan","sequence":"additional","affiliation":[{"name":"Oxford Centre for Magnetic Resonance, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Mills","sequence":"additional","affiliation":[{"name":"Oxford Centre for Magnetic Resonance, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK"},{"name":"Oxford Translational Myeloma Centre, Oxford OX3 7LD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-5070","authenticated-orcid":false,"given":"Marina","family":"Maritati","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarti","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hampshire Hospitals NHS Foundation Trust, Hampshire SO22 5DG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia","family":"Peppercorn","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hampshire Hospitals NHS Foundation Trust, Hampshire SO22 5DG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Oppermann","sequence":"additional","affiliation":[{"name":"Oxford Translational Myeloma Centre, Oxford OX3 7LD, UK"},{"name":"Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire M.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK"},{"name":"Nuffield Department of Surgical Sciences (NDS), Oxford OX3 9DU, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1275-1197","authenticated-orcid":false,"given":"Christopher T.","family":"Rodgers","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Kassim","family":"Javaid","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gooding","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK"},{"name":"Oxford Translational Myeloma Centre, Oxford OX3 7LD, UK"},{"name":"MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK"},{"name":"Oxford Translational Myeloma Centre, Oxford OX3 7LD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-021-00344-2","article-title":"The changing landscape of relapsed and\/or refractory multiple myeloma (MM): Fundamentals and controversies","volume":"10","author":"Encinas","year":"2022","journal-title":"Biomark. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3390\/cancers12051223","article-title":"Treatment of smoldering multiple myeloma: Ready for prime time?","volume":"12","author":"Yee","year":"2020","journal-title":"Cancers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/etm.2021.10764","article-title":"Modern markers for evaluating bone disease in multiple myeloma (Review)","volume":"22","author":"Pop","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/bcj.2011.22","article-title":"Myeloma cells suppress osteoblasts through sclerostin secretion","volume":"1","author":"Colucci","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.blre.2013.08.002","article-title":"Dickkopf-1 is a key regulator of myeloma bone disease: Opportunities and challenges for therapeutic intervention","volume":"27","author":"Zhou","year":"2013","journal-title":"Blood Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3324\/haematol.10943","article-title":"Serum levels of OPG, RANKL and RANKL\/OPG ratios in newly-diagnosed patients with multiple myeloma. Clinical correlations","volume":"92","author":"Goranov","year":"2007","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","article-title":"RANK ligand and osteoprotegerin in myeloma bone disease","volume":"101","author":"Sezer","year":"2003","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/bonekey.2013.95","article-title":"Clinical utility of serum sclerostin measurements","volume":"2","author":"Clarke","year":"2013","journal-title":"BoneKEy Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.13509","article-title":"Whole body diffusion weighted MRI\u2014A new view of myeloma","volume":"171","author":"Messiou","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2015.338","article-title":"Whole-body diffusion-weighted MRI: A new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn","year":"2016","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1759720X12466608","article-title":"Wnt signaling in bone formation and its therapeutic potential for bone diseases","volume":"5","author":"Kim","year":"2013","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ndt\/gfr270","article-title":"Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients","volume":"27","author":"Cejka","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-019-1452-5","article-title":"Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: A cross-sectional study","volume":"20","author":"Kuo","year":"2019","journal-title":"BMC Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.nefro.2020.04.009","article-title":"The correlation between sclerostin and bone mineral density in renal transplant recipients","volume":"40","author":"Coban","year":"2020","journal-title":"Nefrolog\u00eda"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2265.2011.04315.x","article-title":"Serum sclerostin levels were positively correlated with fat mass and bone mineral density in Central South Chinese postmenopausal women","volume":"76","author":"Sheng","year":"2012","journal-title":"Clin. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Peng, J., Dong, Z., Hui, Z., Aifei, W., Lianfu, D., and Youjia, X. (2021). Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis. BMC Musculoskelet. Disord., 22.","DOI":"10.1186\/s12891-021-04365-8"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Vargas-Mu\u00f1oz, V.M., Jimenez-Andrade, M.C., Villarreal-Salcido, J.C., Martinez-Martinez, A., Acosta-Gonzalez, R.I., Lugo-Zamudio, G.E., Conde-Mercado, J.M., Barbosa-Cobos, R.E., Matias-Morales, F.A., and Ramirez-Rosas, M.B. (2015). Association between Sclerostin and Bone Mineral Density in a Mexican Sample of Women with Rheumatoid Arthritis: A Pilot Study. J. Arthritis, 1\u20136.","DOI":"10.4172\/2167-7921.S1-008"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1159\/000446278","article-title":"Sclerostin and Bone Aging: A Mini-Review","volume":"62","author":"Hay","year":"2016","journal-title":"Gerontology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2007-03-082529","article-title":"Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma","volume":"110","author":"Qian","year":"2007","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0609.2008.01164.x","article-title":"Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment","volume":"82","author":"Heider","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bone.2017.10.004","article-title":"DKK1 and sclerostin are early markers of relapse in multiple myeloma","volume":"113","author":"Mabille","year":"2017","journal-title":"Bone"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Girgis, S., Lin, S.X., Pillarisetti, K., Verona, R., Vieyra, D., Casneuf, T., Fink, D., Miao, X., Chen, Y., and Stephenson, T. (Blood Adv., 2022). Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma, Blood Adv., in press.","DOI":"10.1182\/bloodadvances.2022007625"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/jmri.22070","article-title":"Comparison of apparent diffusion coefficients and distributed diffusion coefficients in high-grade gliomas","volume":"31","author":"Kwee","year":"2010","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/RLI.0b013e3181b4c10e","article-title":"Correlation of ADC and T2 Measurements With Cell Density in Prostate Cancer at 3.0 Tesla","volume":"44","author":"Gibbs","year":"2009","journal-title":"Investig. Radiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1148\/radiol.13131529","article-title":"Whole-Body Diffusion-weighted MR Imaging for Assessment of Treatment Response in Myeloma","volume":"271","author":"Giles","year":"2014","journal-title":"Radiology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3389\/fonc.2019.01362","article-title":"Apparent Diffusion Coefficient for Distinguishing Between Malignant and Benign Lesions in the Head and Neck Region: A Systematic Review and Meta-Analysis","volume":"9","author":"Surov","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"109403","DOI":"10.1016\/j.ejrad.2020.109403","article-title":"The utility of ADC value in diffusion-weighted whole-body MRI in the follow-up of patients with multiple myeloma. Correlation study with 18F-FDG PET-CT","volume":"133","author":"Paternain","year":"2020","journal-title":"Eur. J. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mesguich, C., Latrabe, V., Hulin, C., Lascaux, A., Bordenave, L., Hindi\u00e9, E., and Marit, G. (2021). Prospective Comparison of 18-FDG PET\/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant. Cancers, 13.","DOI":"10.3390\/cancers13081938"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1002\/cam4.4136","article-title":"Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry","volume":"10","author":"Belotti","year":"2021","journal-title":"Cancer Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/95\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:49:23Z","timestamp":1760147363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/95"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15010095"],"URL":"https:\/\/doi.org\/10.3390\/cancers15010095","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,12,23]]}}}